Live Feeds
● LIVE Updated 12m ago · 9 sources tracked

Moderna Swings to Profit, Lifts Outlook as Covid-19 Vaccine Demand Stabilizes

Moderna reported a third-quarter profit and lifted its full-year 2026 revenue forecast, citing stabilizing demand for its Covid-19 vaccine overseas and early traction for newer respiratory and cancer vaccines. The biotech company topped analyst estimates for both earnings and revenue in the quarter. Chief Executive Stephane Bancel said the updated Covid shot is gaining market share internationally, while the pipeline — including a personalized cancer vaccine developed with Merck — is advancing toward key data readouts. Investors have driven the stock to a five-year high largely on oncology optimism, but the latest results underscore that Covid sales remain a substantial revenue engine.

🎙️

Listen to Live Briefing

Real-time synthesized voice briefing · Live Feeds Desk

⏱ ~3 min
Speed:
RSS Source map (9)
⚡ Key Developments & Real-Time Context
Text size:
  • ✓ Moderna swung to a profit in the third quarter.
  • ✓ The company raised its full-year 2026 revenue forecast.
  • ✓ Quarterly earnings and revenues exceeded analyst estimates.
  • ✓ Covid-19 vaccine demand stabilized, particularly overseas.
🛡️ Source Corroboration: 9 independent reporting domains (90% confidence) ⏱ Read time: ~3 min

What changed

Moderna reported a Q3 profit, beat revenue estimates, and increased its 2026 sales outlook based on stronger-than-expected international Covid vaccine demand and early uptake of newer products.

Live updates

  1. Moderna Swings to Q3 Profit, Raises 2026 Outlook on Covid Demand

    Moderna reported a third-quarter profit and lifted its full-year 2026 revenue forecast, citing stabilizing demand for its Covid-19 vaccine overseas and early traction for newer respiratory and cancer vaccines. The biotech company topped analyst estimates for both earnings and revenue in the quarter. Chief Executive Stephane Bancel said the updated Covid shot is gaining market share internationally, while the pipeline, including a personalized cancer vaccine developed with Merck, is advancing toward key data readouts. Investors have driven the stock to a five-year high largely on oncology optimism, but the latest results underscore that Covid sales remain a substantial revenue engine.

    Why it matters

    After years of declining pandemic sales, Moderna is attempting to prove its mRNA platform can deliver blockbusters beyond Covid. The profit swing and raised guidance signal that the transition to a seasonal respiratory vaccine business may be more durable than skeptics expected. At the same time, the market's 700% rally since 2020 lows has been fueled primarily by cancer-vaccine hype, making the upcoming oncology data a critical test of that valuation.

    What is confirmed

    • Moderna swung to a profit in the third quarter.
    • The company raised its full-year 2026 revenue forecast.
    • Quarterly earnings and revenues exceeded analyst estimates.
    • Covid-19 vaccine demand stabilized, particularly overseas.
    • CEO Stephane Bancel said newer vaccines are gaining traction.
    • Moderna shares have risen roughly 700% from pandemic lows on cancer-vaccine optimism.

    Still unconfirmed

    • The personalized cancer vaccine developed with Merck is the primary driver of the stock's five-year high.

    What to watch next

    • Clinical data readouts for the mRNA-4157 cancer vaccine with Merck
    • U.S. fall vaccination rates for the updated Covid shot
    • Regulatory decisions on RSV and combination respiratory vaccines
    Sources used for this update (9)
    1. www.marketscreener.com — Global Stocks Fall on Higher Oil Prices, AI Pullback | MarketScreener
    2. CNBC — Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction
    3. Financial Times — Moderna swings to profit as momentum for cancer vaccine builds
    4. Reuters — Moderna lifts annual revenue forecast on strong COVID vaccine demand overseas
    5. WSJ — Moderna Swings to Profit, Lifts Outlook as Covid-19 Vaccine Demand Stabilizes
    6. Investor's Business Daily — Moderna Hits 5-Year High; But The Real Story Is Still In Cancer
    7. Barron's — Moderna Stock Is Up 700% on Cancer Vaccine Hype. Earnings Reveal That Covid Still Counts.
    8. Yahoo Finance — Moderna (MRNA) Q3 Earnings and Revenues Top Estimates
    9. Fierce Pharma — Moderna's COVID vaccine carries stellar Q3 revenue beat
    confidence 90%
📊

Community Sentiment: How do you assess this situation?

Voice your perspective · Real-time aggregated sentiment from the Live Feeds community